Lahrichi A, Hali F, Baline K, Fatoiki F Z El, Chiheb S, Khadir K
Department of dermatology's diseases, CHU Ibn Rochd, 20050 Casablanca, Morocco; Faculty of medicine and pharmacy, University Hassan II, Casablanca, Morocco.
Department of dermatology's diseases, CHU Ibn Rochd, 20050 Casablanca, Morocco; Faculty of medicine and pharmacy, University Hassan II, Casablanca, Morocco.
Arch Pediatr. 2018 Nov;25(8):449-451. doi: 10.1016/j.arcped.2018.09.002. Epub 2018 Oct 22.
Infantile hemangiomas are the most common childhood vascular tumors. Propranolol is a β-adrenergic blocker that has proven effective in the treatment of this tumor. Numerous studies around the world have been published, describing satisfactory responses in pediatric populations with a higher cure rate and fewer adverse effects than when using corticosteroids. The aim of this study was to evaluate the efficacy and adverse effects of propranolol in Moroccan pediatric patients diagnosed with infantile hemangioma who were treated with oral propranolol. A prospective study was conducted from May 2009 to May 2017 in the department of dermatology of a hospital in Casablanca. All the patients who had infantile hemangioma were included. The study comprised 121 patients with infantile hemangioma: 90 girls and 31 boys. The mean age was 6 months. The majority of hemangiomas were mixed (63%) and located on the face and neck. The treatment was well tolerated by all the patients. The dosage of propranolol was gradually increased from 1mg to 2mg/kg/day. We noted a decrease in coloration after 48hours. The healing period for ulcerated hemangiomas was 20 days. A decrease in size was noted after 1 month, while a decrease in palpebral obstruction occurred after 3 days. Treatment with propranolol in this group of Moroccan pediatric patients proved to be safe and effective at a dose of 2 mg/kg/day, reducing the size and coloration of the hemangioma. Treatment should be stopped at an appropriate time, which is determined primarily by the lesion regression rate after propranolol treatment.
婴儿血管瘤是儿童期最常见的血管肿瘤。普萘洛尔是一种β-肾上腺素能阻滞剂，已被证明对治疗这种肿瘤有效。世界各地已发表了大量研究，描述了儿科患者的满意反应，与使用皮质类固醇相比，治愈率更高，不良反应更少。本研究的目的是评估普萘洛尔对摩洛哥诊断为婴儿血管瘤并接受口服普萘洛尔治疗的儿科患者的疗效和不良反应。2009年5月至2017年5月在卡萨布兰卡一家医院的皮肤科进行了一项前瞻性研究。所有患有婴儿血管瘤的患者均被纳入。该研究包括121例婴儿血管瘤患者：90名女孩和31名男孩。平均年龄为6个月。大多数血管瘤为混合型（63%），位于面部和颈部。所有患者对治疗耐受性良好。普萘洛尔的剂量从1mg逐渐增加至2mg/kg/天。我们注意到48小时后颜色变浅。溃疡型血管瘤的愈合期为20天。1个月后观察到大小减小，而睑裂阻塞在3天后减轻。在这组摩洛哥儿科患者中，以2mg/kg/天的剂量使用普萘洛尔治疗被证明是安全有效的，可减小血管瘤的大小和颜色。治疗应在适当的时候停止，这主要由普萘洛尔治疗后的病变消退率决定。
